Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Burkitt Lymphoma 2 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Multiple Myeloma 1 Metastatic Solid Tumors 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Gynecological Solid Tumors 1 Breast Neoplasms 1

Interventions

Iodine-131 14 trametinib 9 dabrafenib 9 Thyroidectomy 9 Surgical Procedures, Operative 9 lenvatinib 8 Thyroxine 8 Magnetic Resonance Spectroscopy 8 pembrolizumab 7 Paclitaxel 7 anlotinib 6 Thyrotropin Alfa 6 selpercatinib 5 Sorafenib 5 Saline Solution 5 Radiofrequency Ablation 5 Everolimus 5 pazopanib 4 Vemurafenib 4 Sunitinib 4 Radiotherapy 4 Nivolumab 4 Fluorodeoxyglucose F18 4 Dexmedetomidine 4 Cyclophosphamide 4 Biopsy, Fine-Needle 4 Biopsy 4 Bevacizumab 4 apatinib 3 Triiodothyronine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thyroid Neoplasms × Antibodies, Bispecific × Clear all

NCT00467506 2011-11-11

RIT in MTC

Nantes University Hospital

Phase 2 Completed

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡